Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cessatech ASFRA:8GN +30.49%27 EV-to-EBITDA is -12.86 as of Sep. 17, 2026. GuruFocus rates FRA:8GN with a GF Score™ of 27/100. The stock has 2 warning signs investors should review. Among 435 Biotechnology companies, Cessatech AS ranks worse than 229884.83% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Cessatech AS's enterprise value is €22.60 Mil.
Cessatech AS's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was €-1.76 Mil. Therefore, Cessatech AS's EV-to-EBITDA for today is -12.86.
The historical rank and industry rank for Cessatech AS's EV-to-EBITDA or its related term are showing as below:
FRA:8GN'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -28.62 Med: -12.06 Max: -6.01
Current: -12.87
During the past 6 years, the highest EV-to-EBITDA of Cessatech AS was -6.01. The lowest was -28.62. And the median was -12.06.
FRA:8GN's EV-to-EBITDA is ranked worse than 100% of 435
companies
in the Biotechnology industry
Industry Median: 12.6
vs FRA:8GN: -12.87
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Cessatech AS's PE Ratio (TTM) for today is calculated as:
Cessatech AS's share price for today is €1.455.
Cessatech AS's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.071.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Cessatech AS's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:8GN vs VRTX, REGN, MRNA: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Cessatech AS's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cessatech AS EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cessatech AS's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Cessatech AS's EV-to-EBITDA falls into.
Cessatech AS's current Enterprise Value is €22.60 Mil.
Cessatech AS's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1.76 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cessatech AS (FRA:8GN) has a EV-to-EBITDA of -12.86 as of Sep. 17, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Cessatech AS. According to the industry distribution chart, Cessatech AS ranks #999999 out of 435 companies in the Biotechnology industry.
Is Cessatech AS's EV-to-EBITDA too high?
Cessatech AS's current EV-to-EBITDA is -12.86. Based on the distribution chart, Cessatech AS ranks #999999 out of 435 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Cessatech AS has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Cessatech AS's EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Cessatech AS ranks #999999 out of 435 companies for EV-to-EBITDA. This places Cessatech AS in the lower half of its industry. The industry median EV-to-EBITDA is 12.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 12.60, based on 435 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Cessatech AS. For the Biotechnology industry, the median EV-to-EBITDA is 12.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cessatech AS's current EV-to-EBITDA is -12.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cessatech AS stock overvalued right now?
Cessatech AS (FRA:8GN) has a current EV-to-EBITDA of -12.86. The current EV-to-EBITDA is -12.86. Cessatech AS's overall GF Score™ is 27/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Cessatech AS (FRA:8GN), the current EV-to-EBITDA is -12.86 as of Sep. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cessatech AS is a pharmaceutical company committed to developing and commercializing evidence-based medicines for children for the treatment of paediatric acute pain. The company is advancing a pipeline comprising three assets, all addressing an unmet medical need in the treatment of children. The main candidate, CT001, a fixed-dose nasal spray for treating acute pain in children, is in the pre-launch phase in the U.S. and the EU. CT002, a non-invasive intranasal sedation for children undergoing medical procedures (e.g., MRI scans), has an approved PIP in the EU. CT003, a topical anaesthetic, is currently in pre-clinical development.
27GF Score
Get the complete analysis for FRA:8GN
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:8GN has been successfully added to your 
